Matthew Lunning
DO
Associate Professor of Internal Medicine, Oncology and Hematology
👥Biography 个人简介
Matthew Lunning is a lymphoma specialist who has contributed to clinical development of tazemetostat, an EZH2 inhibitor approved for relapsed/refractory follicular lymphoma with EZH2 mutations and as a later-line option for wild-type EZH2 disease. His work evaluates predictive biomarkers for EZH2 inhibitor activity and combinations with anti-CD20 antibodies. He studies epigenetic mechanisms of lymphomagenesis and resistance to targeted epigenetic therapies. He is active in SWOG and other cooperative group lymphoma trials.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Matthew Lunning 的研究动态
Follow Matthew Lunning's research updates
留下邮箱，当我们发布与 Matthew Lunning（University of Nebraska Medical Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment